KELOWNA, BC / ACCESSWIRE / April 20, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received notifications of four new patents either awarded or allowed.
In Japan, Lexaria has received a new patent under its Patent Family #3: Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents. This is Lexaria's 5th awarded patent in Japan, providing strength to our growing Japanese patent portfolio. Lexaria has existing patents under this Patent Family in Australia, India, Japan, and Mexico.
In Australia, Lexaria has received a new patent under its Patent Family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. This is Lexaria's 10th patent in Australia and only our second patent in this Patent Family, following a similar patent award in 2022 in the USA.
In Canada, Lexaria has been advised that a new patent under our Patent Family #8: Compositions Infused With Nicotine Compounds and Methods of Use Thereof has been allowed. This is Lexaria's second patent in this Patent Family and follows a similar patent issuance in Australia in 2022.
In the USA, Lexaria has been advised that a new patent under our Patent Family #21: Compositions and Methods for Treating Hypertension has been allowed. Lexaria believes this patent could be of particular importance related to the Company's pursuit of utilizing DehydraTECH-CBD in relation to its expected upcoming FDA Investigational New Drug application. The outcomes of our series of hypertension studies already completed were instrumental in achieving this patent. This will be Lexaria's first patent in this Patent Family.
The global cardiovascular drugs market was worth US$146.5 billion in 2022 and expected to reach $173.5 billion in 2026 and by geography, North America is the biggest market in the world making US patent protection a necessity in the pursuit of commercial markets.
When a patent is "allowed", it means we have been notified by the patent office that they have determined they will soon grant the patent, often subject to some administrative tasks and/or fees. Lexaria is continuously pursuing additional patent protection for its innovative DehydraTECH drug delivery technology. After the awarding of these patents, Lexaria's total patent portfolio will have grown to 32 granted patents worldwide.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 28 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
George Jurcic - Head of Investor Relations
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View source version on accesswire.com: